Although no dedicated trial has been designed to specifically address the effects of pioglitazone on primary stroke prevention in insulin resistance/T2DM patients, it is reasonable that pioglitazone administration may be an effective strategy for primary stroke prevention in insulin-resistant/T2DM patients with nascent AF. This evidence concerns the gene INS and type 2 diabetes mellitus.